A B S T R A C T Nitroglycerin (NTG), the agent most commonly used to treat acute angina pectoris, is a vasodilator whose mechanism of action remains unknown. We hypothesized that NTG might induce endothelial cells to synthesize prostacyclin (PGI2), a known vasodilator and inhibitor ofplatelet aggregation. Therefore, cultured human endothelial cells were incubated with NTG at various concentrations for 1-3 min. PGI2 biologic activity in the endothelial cell supernates was assayed by inhibition of platelet aggregation in vitro. The concentration of 6-keto-PGFie, the stable hydrolysis product of PGI2, was measured by specific radioimmunoassay.
INTRODUCTION
Nitroglycerin (NTG)l is a vasodilator of unknown mechanism which has been used clinically since 1855 for the treatment of angina pectoris (1) . In addition to its vasodilating properties, NTG is an inhibitor of platelet aggregation in vitro, though only at high, suprapharmacologic concentrations (2) (3) (4) . Thus, it belongs to a diverse group of agents including alcohol, dipyridamole, nitroprusside, verapamil, hydralazine, and others, which have both vasodilatory and antiplatelet activities (5) (6) (7) (8) .
It has been noted by Garratini (5) that for many of these drugs, there is a marked disparity between concentrations which inhibit platelet aggregation in vitro and therapeutic plasma levels obtained in vivo. The minimal in vitro inhibitory levels can be several orders of magnitude higher than the in vivo counterparts. Thus, if these agents inhibit platelet activity in vivo when used therapeutically, they must act indirectly. The mechanism of that action may also be responsible for the vasodilation. We hypothesized that NTG might stimulate the production of a second substance in vivo which in turn would decrease vascular tone and inhibit platelet activity. Prostacyclin (PGI2) is now well established as a potent, naturally occurring vasodilator and platelet inhibitor (9, 10) . Its properties are thus identical to the class of agents noted above. Furthermore, PGI2 is produced by endothelial cells (11) . We therefore postulated that NTG acts in vivo by stimulating the production of PGI2 by endothelial cells.
This paper demonstrates that NTG induces a significant and dose-related increase in endothelial cell PGI2 synthesis in vitro; the PGI2 produced inhibits platelet function. METHODS Cell culture technique. Human endothelial cells were obtained from umbilical cord veins and cultured in 24-well (16 mm Diam) cluster plates (Costar, Cambridge, Mass.) as described (12, 13) . Cultures were used at confluency in the second or third serial passage. Cell counts were performed as described (11, 12) and any well containing cells > ±+l10% of the mean cell count was rejected from ftirther evaluation.
Human lung fibroblasts (GM 1380, Human Genetic Mutant Cell Repository, Institute for Medical Research, Camden, N. J.) were maintained in minimal essential medium (Flow Laboratories Inc., Rockville, Md.) with 20% fetal calf serumi in T75 flasks until passage into 24-well cluster plates. Cultures were then used at confluency.
Treatment ofendothelial cells with NTG. NTG as a sterile aqueous solution containing solely NTG (0.5 mg/ml) and lactose (4.5 mg/ml) was obtained as a gift from Eli Lilly & Co., Indianapolis, Ind. Because of the recent demonstration that NTG is adsorbed to plastic, serial 10-fold dilutions in sterile water were prepared in glass tubes immediately prior to use (14) . Light-shielding was used although it has recently been shown that lactose-adsorbed, aqueous NTG solutions do not decompose in light (15) .
Each monolayer of endothelial cells was washed twice with a buffer containing 10 mM Hepes (pH 7.35 at 37°C), 137 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5.5 mM glucose (buffer I). The cultures were agitated as little as possible to prevent shear-induced PGI2 production. 490 ,ul of this buffer and 10 ,A of NTG solution were mixed to yield final NTG concentrations of 100 fg/inl to 10 ng/ml and then placed over the endothelial cell monolayer immediately after the second wash. After it was determined in preliminary experiments that maximal PGI2 release was obtained after incubation for 3 min at 37°C, all incubations were performed for 3 min at 37°C. Supernates were then removed, rapidly frozen, and then stored at -70°C until use.
In each experiment the following control incubations with endothelial cells were performed: (a) buffer I containing 20 ,M sodium arachidonate (AA, Sigma Chemical Co., St. Louis, Mo.); (b) buiffer alone; and (c) buffer containing 90 ,ug/ml lactose (the vehicle for NTG; Sigma Chemical Co.). In addition, NTG solutions were incubated in wells without endothelial cells, which had been treated identically (gelatincoated, medium-conditioned) to those containing cultured cells. Finally in each experiment, the NTG, AA and buffer solutions were each incubated with endothelial cells which had been pretreated with either aspirin (ASA) (Sigma Clhemiical Co.) or 15-hydroperoxy arachidonic acid (a gift from Dr. Aaron Marcus) by methods described (16, 17) .
Platelet aggregation and thromboxane B2 production. Platelet-rich plasma (PRP) was prepared from venous blood and aggregation studies performed by methods described (18) . Inhibition of aggregation was quantitated either by expressing the increase in light transmission 5 min after the addition of the stimulus as a percentage of control (method A) or by determining the area under the curve from stimulus to the 5-min mark by planimetry (planimeter No. 123A, Dietzgen Corp., Des Plaines, Ill.) and expressing it as a percentage of the area under the control curve (method B) (19) . Because of the length of experiments, control aggregations were performed every 15 min in each channel to verify stability of the platelet response.
For the measurement of platelet thromboxane (TX)A2 production, platelet samples were prepared by a modification of the method of Fitzpatrick and Gorman (20) . 5 min after addition of the stimulus to each aggregation cuvette, a 100-/l sample was removed, immediately added to 900 ,ul of buffer I containing indomethacin 2 ,ug/ml, vortexed, and frozen in a dry ice-acetone bath at -70°C. Samples were subsequently thawed, spun at 12,500 g for 3 min and the supemates removed and stored at -70°C for testing in the radioimmunoassay (RIA) for TXB2 as described below.
Studies on the platelet inhibitory effect of NTG. Inhibition of platelet aggregation by NTG was studied using the following aggregating agents (expressed as final concentration in the cuvette): (a) Sodium arachidonate (Sigma Chemical Co.), 0. (New England Nuclear, 150 Ci/mmol) and anti-sera at 1:4800 was otherwise perforned in the same way as the 6-ketoPGFj,, radioimmunoassay described above. The range of sensitivity for TXB2 was 3-1,000 pg with 50% binding at 30-40 pg. Cross reactivities were as follows: PGF2, 0.6%, 0.06%; PGF2a, 0.5%, PGE1, 0.2%; 6-keto-PGFI, and 6-keto-PGE1 both < 0.02%; 13,14 dihydro 6,15-diketo-PGF1,. both 40 (4) .
To determine whether NTG inhibited platelet TXA2 production, RIA for TXB2, the stable end product of TXA2, was performed on samples of PRP treated with various concentrations of NTG. The results are shown in Fig. 1 . NTG caused a statistically significant decrease in TXB2 production only at concentrations of NTG2 100 ng/ml, which as shown in Table I , parallels the inhibition of platelet aggregation. Studies in ASA-treated platelets demonstrated that NTG also inhibited primary phase aggregation induced by collagen, epinephrine, or U-44069 (data not shown). Thus, it is likely that NTG does not inhibit TXA2 synthesis directly, but rather the inhibition is secondary to some other platelet inhibitory effect.
As shown in Table I and Fig. 1 neither platelet aggregation nor TXB2 synthesis was significantly inhibited at concentrations of NTG < 100 ng/ml. How- (10, 29) and also obtained by us using synthetic gation. To verify that the inhibition of platelet aggregation by supernates of NTG-treated endothelial cells depends on the presence of PGI2, a series of control experiments was performed. When endothelial cell cyclooxygenase was inactivated by pretreatment with 50 ,uM ASA for 2 h (16), production of the inhibitor elicited from endothelial cells by NTG was completely suppressed; RIA of the supernate showed that 6-ketoPGFi, production was inhibited by more than 95%.
Inhibition of PGI2 synthetase by preincubation of endothelial cells with 20 ,ug/ml 15-hydroperoxy-AA for 15 min also completely abolished production of the inhibitor and RIA of these supernates showed >85% inhibition of NTG-induced PGI2 production. On the basis ofthese results, it is concluded that the inhibitory effect of the supernates of NTG-exposed endothelial cells depends on PGI2. Furthermore, the inhibitor in these supernates was not generated by exposure to the endothelial cells to the buffer-vehicle alone and RIA demonstrated subinhibitory concentrations of 6-keto-PGFia in these samples. Finally, NTG alone after incubation in buffer I in cell-free gelatin coated, medium conditioned wells did not inhibit platelet aggregation.
A heat lability study was performed to further characterize the inhibitor. Because it has been shown that endothelial cells incubated with AA produce PGI2 (11, 17) , we compared the decay rates at 370C of inhibitors in supernates from endothelial cells treated with NTG or with AA. The decay rates of the two inhibitors of platelet aggregation were identical (data not shown), further suggesting that the inhibitor in NTG-treated endothelial cell supemates is PGI2.
The dose-response relationship between NTG and 6-keto-PGF,l, production by endothelial cells was obtained by combining the data from six separate experiments and is shown in Fig. 3 . The amount of 6-keto-PGF1Q produced was significantly greater than control (P < 0.01) at all NTG concentrations .0.1 ng/ml. For example, NTG 10 ng/ml increased 6-keto-PGF10 production by a mean value of 63%. Lower doses of NTG elicited production of smaller amounts of 6-ketoPGF1a,. Samples from these six experiments were also tested for the presence of PGI2 biologic activity.
Supernates from endothelial cells treated with NTG at concentrations -10 pg/ml incubated with PRP for 1 min significantly inhibited collagen-induced platelet aggregation (P < 0.001, n = 10). Similar inhibition was obtained using AA or epinephrine as the aggregating 766 R. I. Levin agents. As noted, pretreatment of the endothelial cells with either ASA or 15-hydroperoxy-AA completely abolished the production of the inhibitor of platelet aggregation and the production of 6-keto-PGF1,.
To determine if there were any interactions between NTG, PGI2, and endothelial cells that might have led to artifactual results in the RIA for 6-keto-PGFa,., a series of recovery studies were performed. Synthetic PGI2 (300-1200 pg/ml) was incubated in triplicate in cluster plates under four conditions: (a) in buffer I in cell-free wells; (b) in buffer I overlying ASA-treated endothelial cells; (c) in buffer I containing NTG at varying concentrations in cell-free wells; and (d) in buffer I containing NTG overlying ASA-treated endothelial cells. Recovery was virtually identical under the four conditions. When these data were analyzed by a three-way analysis of variance (the three factors being PGI2, NTG, and ASA-treated endothelial cells), the only factor that significantly affected the amount of 6-keto-PGF1, recovered was the amount of PGI2 added (P < 0.0001). Neither NTG (P = 0.363) nor the presence of ASA-treated endothelial cells (P = 0.63) altered the recovery of 6-keto-PGF1,. Further, none of the possible two-way interactions nor the three-way interaction was statistically significant. Thus, neither NTG, endothelial cells, nor their combination caused Tack-Goldman v an alteration in immunologically assayable 6-ketoPGFia.
Synergy of NTG and PGI2 in the inhibition of platelet aggregation. It has recently been reported that NTG at suprapharmacologic concentrations (>1 jig/ml) is synergistic with PGI2 in the inhibition of platelet aggregation in guinea-pig PRP (30) . Therefore, we investigated the possibility that synergy was contributing to the inhibition ofplatelet aggregation in our experiments by studying the ability of combinations of synthetic PGI2 and NTG to inhibit aggregation in PRP. When suprapharmacologic doses of NTG (.1 ,ug/ml) were combined with doses of PGI2 that alone inhibited platelet aggregation 8-67% (0.6-1.5 nM or 0.21-0.52 ng/ml), the combinations synergistically inhibited platelet aggregation in six separate experiments (in all experiments the test for synergy (interaction) by two-way analysis of variance was significant P < 0.01). However, in five experiments, when NTG at pharmacologic doses (0.1-10 ng/ml) was combined with these concentrations of PGI2, the combinations did not exhibit synergy in inhibiting aggregation. When these data were analyzed by two-way analysis of variance, the only significant factor affecting aggregation was the concentration of PGI2 (P c 0.0001, five experiments). Neither NTG (P > 0.2, five experiments) nor the interaction of NTG and PGI2 (P = 0.06-0.92, 5 experiments) altered the extent of aggregation. Thus, the inhibition of platelet aggregation caused by supernates of NTG-treated endothelial cells is not due to synergy between the NTG remaining in the supernate and the PGI2 produced by the endothelial cells.
Because of the possibility raised in recent reports (31, 32) that platelets might be capable of metabolizing inactive 6-keto-PGFl,, to the platelet inhibitor 6-keto-PGE,, we also investigated whether NTG interacted with 6-keto-PGF1,, to inhibit aggregation. No inhibition of aggregation was noted when PRP was incubated either with 6-keto-PGFi,, alone or with 6-keto-PGFi,,, and NTG for min. This demonstrated that the inhibition of platelet aggregation by supemates of NTG-treated endothelial cells was not secondary to the conversion of 6-keto-PGF,, to some active inhibitory metabolite by the platelets.
DISCUSSION
In this paper, we have demonstrated that NTG at clinically attainable concentrations (0.1-10 nglml) induces a dose-dependent increase in endothelial cell PGI2 production in vitro, as measured both by RIA for 6-keto-PGF,1, and by inhibition of platelet aggregation. Pretreating the endothelial cells with either ASA or 15-hydroperoxy-AA blocked both the production of PGI2 as measured by RIA and the inhibition of platelet aggregation. These results also demonstrate that the inhibition of platelet aggregation by these endothelial cell supemates was not due to adenosine, another platelet inhibitory metabolite (33) released from endothelial cells by various stimuli (34) , because treatment of endothelial cells with aspirin has no effect on their release of adenosine (34, 35) . Heating the endothelial cell supemates at 37°C, a condition known to inactivate PGI2 but not other platelet-inhibitory prostaglandins such as PGE, or 6-keto PGE, (32, 36) , inactivated the inhibitor. These experiments indicated that PGI2 was the inhibitor of platelet aggregation present in the supernates of NTGtreated endothelial cells.
We have further demonstrated that the observed inhibition of platelet aggregation by these supernates is not due to synergy between PGI2 and NTG remaining in the supernate, since PGI2 and NTG synergistically inhibit platelet aggregation only at suprapharmacologic concentrations of NTG. Since this synergy is not present in vitro at clinically attainable concentrations of NTG, it is unlikely to be present in vivo after therapeutic administration of the drug.
The inhibition of platelet aggregation caused by the supernates of NTG-treated endothelial cells was rarely total. However, it has been estimated that the ratio of endothelial cells to platelets in the capillary circulation is -1:1 (17 Several studies have been performed attempting to demonstrate that NTG induces the production of PGC2 and other prostaglandins. Morcillio et al. (38) demonstrated that NTG, when infused into dogs, caused a decrease in coronary artery resistance which was accompanied by an increase in E series prostaglandins. Since indomethacin diminished both of these effects, it was suggested that NTG acted in part through the prostaglandin system. In contrast, Neichi et al. (39) (42) (43) (44) (45) . NTG may also relieve angina by causing relaxation of coronary artery spasm (46) , and by shifting blood flow from normally perfused to ischemic myocardium in the absence of peripherally mediated hemodynamic changes (47) . We have shown that intact monolayers of human endothelial cells in vitro release PGI2 in response to clinically attainable concentrations of NTG. The PGI2 produced inhibits platelet aggregation. These data suggest that the vasodilating properties of NTG noted above are, at least in part, indirect and due to the induction by NTG of endothelial cell PGI2 synthesis. The mechanism by which PGI2 induces vasodilation is unclear, though it may be related to its ability to alter cyclic nucleotide levels and calcium ion fluxes (48) . Studies attempting to relate the direct effect of NTG to such alterations have thus far been inconclusive (49) (50) (51) (52) (53) (54) .
In conclusion, current available data suggest that the mechanism of NTG-induced vasodilation is multifactorial. The findings described here provided a basis for understanding in part how NTG might relieve myocardial ischemia by altering the PGI2:TXA2 ratio in favor of PGI2 excess with resultant vasodilation and inhibition of platelet function.
